MGL-3196 Completed Phase 2 Trials for Heterozygous Familial Hypercholesterolemia Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03038022Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)